Bisphosphonates are the most clinically important class of antiresorptive
agents available to treat diseases characterized by osteoclast-mediated bone
Currently, seven bisphosphonates have the approval of the United States
Food and Drug Administration.
The most common adult diseases treated with bisphosphonates include
osteoporosis, Paget disease, and metastatic bone disease.
The treatment of pediatric disorders such as osteogenesis imperfecta and
fibrous dysplasia with bisphosphonates has gained momentum, and initial
investigations have demonstrated an acceptable safety profile.
Currently, there is a lack of long-term follow-up data, which will be
necessary for the development of responsible guidelines for therapy.